Serdemetan
| CAS No. | 881202-45-5 |
|---|---|
| MDL No. | MFCD16620518 |
| MF | C21H20N4 |
| MW | 328.40 |
| InChI Key | CEGSUKYESLWKJP-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Serdemetan is an orally bioavailable HDM2 antagonist with potential antineoplastic activity. It inhibits the binding of HDM2 to the transcriptional activation domain of p53, preventing proteasome-mediated degradation of p53 and restoring p53 signaling, which may induce tumor cell apoptosis. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and is implicated in cancer cell proliferation and survival.
| CAS No. | 881202-45-5 |
|---|---|
| Product Name | Serdemetan |
Associated Conditions
neoplasm
* The information provided here is compiled from public sources and is for reference only.